Corrie A. Painter

Corrie A. Painter

Auto-generated profile, based on publicly available information

Corrie A. Painter

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JDJoana Damas
Joana Damas
GHGraham M. M Hughes
Graham M. M Hughes
KKKathleen C. Keough
Kathleen C. Keough
CPCorrie A. Painter
Corrie A. Painter
NPNicole S. Persky
Nicole S. Persky
HLHarris Lewin
Harris Lewin
Significance: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19, a major pandemic that threatens millions of human lives and the global economy. We identified a large number of mammals that can potentially be infected by SARS-CoV-2 via their ACE2 proteins. This can assist the identification of intermediate hosts for SARS-CoV-2 and hence reduce the opportunity for a future outbreak of COVID-19. Among the species we found with the highest risk for SARS-CoV-2 infection are wildlife and endangered species. These species represent an opportunity for spillover of SARS-CoV-2 from humans to other susceptible animals. Given the limited infectivity data for the species studied, we urge caution not to overinterpret the predictions of the present study.

10 February 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CPCorrie A. Painter
Corrie A. Painter
EJEsha Jain
Esha Jain
BTBrett N. Tomson
Brett N. Tomson
MDMichael Dunphy
Michael Dunphy
RSRachel E. Stoddard
Rachel E. Stoddard
NWNikhil Wagle
Nikhil Wagle

10 December 2018 in Nature Genetics
Verified
Journal Article
Closed access
UNUtthara Nayar
Utthara Nayar
OCOfir Cohen
Ofir Cohen
CKChristian Kapstad
Christian Kapstad
MCMichael S. Cuoco
Michael S. Cuoco
AWAdrienne G. Waks
Adrienne G. Waks
NWNikhil Wagle
Nikhil Wagle

23 July 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
MEMesut Eren
Mesut Eren
CPCorrie A. Painter
Corrie A. Painter
JAJames B. Atkinson
James B. Atkinson
PDPaul Declerck
Paul Declerck
DVDouglas E. Vaughan
Douglas E. Vaughan
Background — Plasminogen activator inhibitor-1 (PAI-1) regulates fibrinolysis and has been reported to be an independent risk factor for ischemic cardiovascular events. This study describes the age-dependent development of spontaneous coronary arterial thrombi that are associated with evidence of subendocardial myocardial infarction in mice transgenic for human PAI-1. Methods and Results — We generated two independent transgenic mice founder lines that express a stable variant of active human PAI-1 under control of the murine preproendothelin-1 (mPPET-1) promoter. Backcrossed homozygous transgenic animals from founder line I had plasma PAI-1 levels of 23±12 ng/mL. PAI-1 transgenic animals younger than 4 months do not exhibit any evidence of arterial or venous thrombosis. Ninety percent of transgenic animals (n=10) older than 6 months developed spontaneous occlusions of typically multiple, penetrating coronary arteries, with histological evidence of subendocardial infarction identified in 50% of animals. Conclusions — This study shows that chronically elevated levels of PAI-1 are associated with age-dependent coronary arterial thrombosis in mice transgenic for human PAI-1. This is the first study of a murine model of coronary thrombosis that occurs in the absence of severe hypercholesterolemia or multiple genetic manipulations. These findings provide new evidence to support the hypothesis that PAI-1 excess contributes to the development of coronary arterial thrombosis.

1 December 2019 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
KMKatherine Megquier
Katherine Megquier
JTJason Turner-Maier
Jason Turner-Maier
RSRoss Swofford
Ross Swofford
Jon KimJon Kim
Jon Kim
ASAaron L. Sarver
Aaron L. Sarver
KLKerstin Lindblad-Toh
Kerstin Lindblad-Toh
Angiosarcoma is a highly aggressive cancer of blood vessel–forming cells with few effective treatment options and high patient mortality. It is both rare and heterogenous, making large, well-powered genomic studies nearly impossible. Dogs commonly suffer from a similar cancer, called hemangiosarcoma, with breeds like the golden retriever carrying heritable genetic factors that put them at high risk. If the clinical similarity of canine hemangiosarcoma and human angiosarcoma reflects shared genomic etiology, dogs could be a critically needed model for advancing angiosarcoma research. We assessed the genomic landscape of canine hemangiosarcoma via whole-exome sequencing (47 golden retriever hemangiosarcomas) and RNA sequencing (74 hemangiosarcomas from multiple breeds). Somatic coding mutations occurred most frequently in the tumor suppressor TP53 (59.6% of cases) as well as two genes in the PI3K pathway: the oncogene PIK3CA (29.8%) and its regulatory subunit PIK3R1 (8.5%). The predominant mutational signature was the age-associated deamination of cytosine to thymine. As reported in human angiosarcoma, CDKN2A/B was recurrently deleted and VEGFA, KDR, and KIT recurrently gained. We compared the canine data to human data recently released by The Angiosarcoma Project, and found many of the same genes and pathways significantly enriched for somatic mutations, particularly in breast and visceral angiosarcomas. Canine hemangiosarcoma closely models the genomic landscape of human angiosarcoma of the breast and viscera, and is a powerful tool for investigating the pathogenesis of this devastating disease. Implications: We characterize the genomic landscape of canine hemangiosarcoma and demonstrate its similarity to human angiosarcoma.

9 December 2012 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
AGAbigail I Guce
Abigail I Guce
SMSarah E Mortimer
Sarah E Mortimer
TYTaejin Yoon
Taejin Yoon
CPCorrie A Painter
Corrie A Painter
WJWei Jiang
Wei Jiang
LSLawrence J Stern
Lawrence J Stern
HLA-DM interacts with MHCII and promotes peptide exchange. This activity of HLA-DM is regulated by HLA-DO. The crystal structure of the HLA-DO–HLA-DM complex along with mutagenesis and kinetic analyses reveal that HLA-DO adopts a classical MHCII structure and competitively inhibits HLA-DM's activity on MHCII. Mammalian class II major histocompatibility (MHCII) proteins bind peptide antigens in endosomal compartments of antigen-presenting cells. The nonclassical MHCII protein HLA-DM chaperones peptide-free MHCII, protecting it against inactivation, and catalyzes peptide exchange on loaded MHCII. Another nonclassical MHCII protein, HLA-DO, binds HLA-DM and influences the repertoire of peptides presented by MHCII proteins. However, the mechanism by which HLA-DO functions is unclear. Here we have used X-ray crystallography, enzyme kinetics and mutagenesis approaches to investigate human HLA-DO structure and function. In complex with HLA-DM, HLA-DO adopts a classical MHCII structure, with alterations near the α subunit's 310 helix. HLA-DO binds to HLA-DM at the same sites implicated in MHCII interaction, and kinetic analysis showed that HLA-DO acts as a competitive inhibitor. These results show that HLA-DO inhibits HLA-DM function by acting as a substrate mimic, and the findings also limit the possible functional roles for HLA-DO in antigen presentation.